Beperminogene perplasmid is under clinical development by AnGes and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Beperminogene perplasmid’s likelihood of approval (LoA) and phase transition for Arteriosclerosis took place on 09 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 09 Jun 2022 decreased Beperminogene perplasmid’s LoA and PTSR for Thromboangiitis obliterans (Buerger disease).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Beperminogene perplasmid Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Beperminogene perplasmid overview

Beperminogene perplasmid (Collategene) is an hepatocyte growth factor gene therapy drug. It is formulated as injectable solution for intramuscular route of administration. Collategene is indicated for the treatment of for critical limb ischemia.

Beperminogene perplasmid (AMG0001) is under development for the treatment of Occlusive Arterial Disease, arteriosclerosis obliterans, thromboangiitis obliterans (Buerger's disease), lymphedema and chronic arterial occlusion (peripheral arterial disease). The drug candidate is administered through intramuscular and intracardiac route. It is HGF (hepatocyte growth factor) DNA plasmid (nucleic acid) developed using proprietary DNA delivery technology platform. It was also under development for the treatment of critical limb ischemia (CLI) associated with peripheral arterial disease (PAD) Parkinson's disease, ischemic heart disease (IHD), chronic heart failure, coronary artery disease and critical limb ischemia in US and EU.

AnGes overview

AnGes is a biopharmaceutical company, which discovers and develops gene and nucleotide-based drugs and reagents for use in the functional analysis of genetic medications. The company specializes in the research and development (R&D) and practical application of genetic medicines. It has two main projects under development, namely, a hepatocyte growth factor (HGF) plasmid, which is a genetic medicine that improves blood circulation by regenerating blood vessels and NF-KB decoy oligonucleotide. It also develops therapeutic vaccine projects including CIN (cervical intraepithelial neoplasia) therapeutic vaccines. The company has operations in Japan and the US. AnGes is headquartered in Ibaraki, Osaka, Japan.

Quick View Beperminogene perplasmid LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Beperminogene perplasmid
Administration Pathway
  • Intracardiac
  • Intramuscular
  • Parenteral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Gastrointestinal
  • Hematological Disorders
Key Developers
  • Sponsor Company: AnGes
  • Originator: Osaka University
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.